| 60.555 -0.435 (-0.71%) | 05-15 10:18 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 79.42 | 1-year : | 92.76 |
| Resists | First : | 68 | Second : | 79.42 |
| Pivot price | 58.45 |
|||
| Supports | First : | 56.91 | Second : | 50.06 |
| MAs | MA(5) : | 62.27 |
MA(20) : | 57.19 |
| MA(100) : | 59.81 |
MA(250) : | 58.34 |
|
| MACD | MACD : | 1.8 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 63.7 |
D(3) : | 65.6 |
| RSI | RSI(14): 58.8 |
|||
| 52-week | High : | 105 | Low : | 28.39 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ MNPR ] has closed below upper band by 31.2%. Bollinger Bands are 60.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 62.48 - 62.79 | 62.79 - 63.05 |
| Low: | 57.43 - 57.75 | 57.75 - 58.01 |
| Close: | 60.51 - 61.02 | 61.02 - 61.45 |
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
Thu, 14 May 2026
Is Monopar Therapeutics (MNPR) Undervalued After Q1 2026 EPS Bea - GuruFocus
Thu, 14 May 2026
Monopar (NASDAQ: MNPR) ends Q1 with $137.5M cash and funds through 2027 - Stock Titan
Thu, 14 May 2026
Monopar Therapeutics Reports Q1 2026 Financial Results and Updates on ALXN1840 Development for Wilson Disease - Quiver Quantitative
Thu, 14 May 2026
Cash runway to 2027 as Monopar (NASDAQ: MNPR) readies ALXN1840 - Stock Titan
Thu, 14 May 2026
Biotech Monopar readies Wilson disease drug filing, funded into 2027 - Stock Titan
Wed, 13 May 2026
Adage (MNPR) reports 424,195 shares, including 115,000 warrant shares - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 4 (M) |
| Held by Insiders | 23.2 (%) |
| Held by Institutions | 83 (%) |
| Shares Short | 1,720 (K) |
| Shares Short P.Month | 1,650 (K) |
| EPS | -1.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 20.59 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10.4 % |
| Return on Equity (ttm) | -14.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -12 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -33.55 |
| PEG Ratio | 0 |
| Price to Book value | 3.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -34.04 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|